Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Promotheus Laboratories launches ProOnc cancer diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Firm debuts Oct. 15 three new cancer diagnostics based on microRNA technology. ProOnc TumorSource is designed to identify tissue of origin in metastatic tumors; among the 25 tissue types it can identify are cancers of the colon, liver, brain, breast, kidney, lung, ovary, pancreas, prostate and testis, Promotheus says. ProOnc Squamous measures the expression level of a squamous microRNA biomarker to differentiate patients with and without lung cancer. ProOnc Mesothelioma differentiates malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura, the firm says. The home brews are run at a CLIA-certified lab, the company notes
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel